Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy
Abstract
Summary: Purpose: A multicenter, prospective, long‐term, open‐label study to evaluate the effects of levetiracetam on electroencephalogram (EEG) abnormalities and photoparoxysmal response (PPR) of patients affected by juvenile myoclonic epilepsy (JME). Methods: Forty‐eight patients with newly diagnosed JME (10) or resistant/intolerant (38) to previous antiepileptic drugs (AEDs) were enrolled. After an 8‐week baseline period, levetiracetam was titrated in 2 weeks to 500 mg b.i.d. and then increased to up to 3,000 mg/day. Efficacy parameters were based on the comparison and analysis of EEG interictal abnormalities classified as spikes‐and‐waves, polyspikes‐and‐waves, and presence of PPR. Secondary end point was evaluation of EEG and PPR changes as predictive factors of 12‐month seizure freedom. Results: Overall, mean dose of levetiracetam was 2,208 mg/day. Mean study period was 19.3 ± 11.5 months (range 0.3–38). During the baseline period, interictal EEG abnormalities were detected in 44/48 patients (91.6%) and PPR was determined in 17/48 (35.4%) of patients. After levetiracetam treatment, 27/48 (56.2%) of patients compared to 4/48 (8.3%) in the baseline period (p < 0.0001) had a normal EEG. Thirteen of 17 (76.4%) (p < 0.0003) patients showed suppression of PPR. Cumulative probability of days with myoclonia (DWM) 12‐month remission was significantly higher (p < 0.05) in patients with a normal (normalized) EEG after levetiracetam treatment compared to those with an unchanged EEG. Conclusions: Levetiracetam appeared to be effective in decreasing epileptiform EEG abnormalities, and suppressing the PPR in JME patients. This effect, along with a good efficacy and tolerability profile in this population further supports a first‐line role for levetiracetam in the treatment of JMEKeywords
This publication has 38 references indexed in Scilit:
- Placebo-controlled study of levetiracetam in idiopathic generalized epilepsyNeurology, 2007
- Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsyNeurology, 2007
- Long‐Term Outcome of Pattern‐Sensitive EpilepsyEpilepsia, 2006
- Levetiracetam Efficacy in Epileptic Syndromes with Continuous Spikes and Waves during Slow Sleep: Experience in 12 CasesEpilepsia, 2005
- Levetiracetam Induces a Rapid and Sustained Reduction of Generalized Spike-Wave and Clinical AbsenceArchives of Neurology, 2004
- Efficacy of levetiracetam in pharmacoresistant continuous spikes and waves during slow sleepActa Neurologica Scandinavica, 2004
- Exacerbation of juvenile myoclonic epilepsy with lamotrigineNeurology, 2001
- Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating MonotherapyEpilepsia, 2000
- Revisiting the Concept of Identifiable NeuronsBrain, Behavior and Evolution, 2000
- Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmissionNaunyn-Schmiedeberg's Archives of Pharmacology, 1997